Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

60,500 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H21/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 6,050
1.WO/2024/106539LIGAND CONJUGATE SUBSTANCE, NUCLEIC ACID CONTAINING SAME, AND USE THEREOF
WO - 23.05.2024
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
 Appl.No PCT/JP2023/041480 Applicant BONAC CORPORATION Inventor OHGI, Tadaaki
This ligand conjugate nucleic acid represented by general formula (I) [In the formula (I), the symbols are as defined in the specification.] provides a therapeutic and/or prophylactic agent which enables serum stability, delivery to an appropriate organ or cell, and transmembrane delivery, and which can impart high functionality at low production cost.
2.WO/2024/103068BIOMIMETIC LIPOSOMES AND METHODS OF MAKING AND USING THE SAME
WO - 16.05.2024
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
 Appl.No PCT/US2023/079541 Applicant WORCESTER POLYTECHNIC INSTITUTE Inventor BAILEY-HYTHOLT, Christina, M.
This disclosure relates generally to biomimetic proteoliposomes, methods of making and methods of using the same. In particular, this disclosure provides proteoliposomes comprising one or more phospholipid carrier and one or more protein embedded in the one or more phospholipid carrier, wherein the one or more phospholipid carrier comprises a phospholipid composition with similar proportions of phospholipids as a naturally occurring cell type and a phospholipid concentration of about 1-50 mM; and wherein the one or more protein comprises a protein composition with similar proportions of proteins as the naturally occurring cell type.
3.20240158432COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF
US - 16.05.2024
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
 Appl.No 18514386 Applicant CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. Inventor Hu CHENG

A composition comprising dichloroacetic acid and glyoxylic acid, wherein, the content of glyoxylic acid is below 1000 pm, and the preparation method and application of the composition. A process for preparing the composition, comprising: mixing a dichloroacetic acid material having greater than 1000 ppm glyoxylic acid with a glyoxylic acid capture reagent, and a process for preparing oligonucleotides, comprising using the composition. It is found that glyoxylic acid is an impurity in commercially available DCA products, which may cause the oligonucleotides synthesis failure. Ion chromatography can be used to detect glyoxylic acid in dichloroacetic acid and accurately determine its concentration.

4.WO/2024/102984HUMAN AND MURINE OPRM1 PROMOTERS AND USES THEREOF
WO - 16.05.2024
Int.Class A61K 31/711
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
 Appl.No PCT/US2023/079350 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor CORDER, Gregory
The disclosure relates to isolated nucleic acids comprising opioid receptor promoter regions and methods and compositions comprising said isolated nucleic acids.
5.WO/2024/093907LIGAND FOR DELIVERING SIRNA TO EYE AND CENTRAL NERVOUS SYSTEM
WO - 10.05.2024
Int.Class C07D 265/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
281,4-Oxazines; Hydrogenated 1,4-oxazines
30not condensed with other rings
 Appl.No PCT/CN2023/127728 Applicant SHANGHAI RONA THERAPEUTICS CO., LTD. Inventor HUANG, Jinyu
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside a nucleotide, or at a 5' end and/or a 3' end, and is used for improving the ability of a double-stranded RNA to pass through the blood-brain barrier. The present invention further relates to a test kit, a pharmaceutical composition, a cell, a carrier, a double-stranded RNA, or an oligonucleotide comprising the compound of formula (I).
6.WO/2024/093947PRODRUG FOR DELIVERING SIRNA INTO CELL
WO - 10.05.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2023/127941 Applicant SHANGHAI RONA THERAPEUTICS CO., LTD. Inventor HUANG, Jinyu
The present invention provides an oligonucleotide, comprising a compound of formula (Ia), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside the oligonucleotide or at the 5' terminal and/or the 3' terminal, and is used for improving the ability of a double-stranded RNA to pass through a cell membrane. The present invention also relates to a double-stranded RNA, a cell, a pharmaceutical composition and a kit comprising the oligonucleotide.
7.WO/2024/097262CHEMOPROTEOMIC CAPTURE OF RNA BINDING ACTIVITY IN LIVING CELLS
WO - 10.05.2024
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No PCT/US2023/036544 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor HSU, Ku-Lung
Methods of identifying RNA-binding sites in proteins are described. In some embodiments, the methods utilize clickable electrophilic purines (CEPs) to study protein-RNA interactions on proteins through photoaffinity competition with 4-thiouridine (4SU)-labeled RNA in cells. The method can be performed in live cells and can be used to identify druggable sites on RNA-binding proteins, including druggable allosteric sites on RNA-binding proteins.
8.WO/2024/097894COMPOSITIONS AND METHODS OF RIBONUCLEIC ACID VACCINES ENCODING NYE-SO-1
WO - 10.05.2024
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2023/078543 Applicant RNAIMMUNE, INC. Inventor SHEN, Dong
Compositions and methods are provided for potent NYE-SO-1 vaccines for treatment of cancer. The compositions include a pharmaceutical composition containing RNA molecules encoding NYE-SO-1 derived peptides together with a pharmaceutically acceptable carrier. Methods for stimulating system immune responses and treatment are provided, including intratumoral, intravenous, intramuscular, intradermal, and subcutaneous injection.
9.WO/2024/097744DNA-COMPATIBLE WITTIG OLEFINATION OF ON-DNA PEPTIDYL-YLIDES FOR DEVELOPMENT OF ON-DNA PEPTIDOMIMETICS THROUGH DIVERSITY-ORIENTED SYNTHESIS (DOS)
WO - 10.05.2024
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/US2023/078334 Applicant THE ROCKEFELLER UNIVERSITY Inventor FLAJOLET, Marc
The present invention provides methods of generating diverse chemical structures on DNA through Wittig olefination of novel on-DNA phosphorane ylides and Homer- Wadsworth-Emmons reaction of on-DNA β-keto phosphonates. The methods of this invention provide access to DNA-encode libraries (DELs) of diverse peptides, peptidomimetics, chalcone-based molecules, and the like.
10.WO/2024/097310TARGETED NON-CHARGED-NUCLEIC ACID (NCNA) DELIVERY AND RELATED TUMOR PENETRATING NANOCOMPLEXES
WO - 10.05.2024
Int.Class A61K 31/7125
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
 Appl.No PCT/US2023/036624 Applicant IMPILO THERAPEUTICS, INC. Inventor SLACK, David
Provided herein are heterologous non-charged-nucleic acid (NCNA) constructs, tumor-penetrating-nanocomplex (TPNs); and related methods of making and using same for treating a variety of diseases.
# -